- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Patricia Coyle on Considerations in Choosing a DMT for MS
Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.
Transcript
What are some of the considerations that clinicians should take into account when choosing a disease-modifying therapy?
Well, I think there are multiple factors in shared-decision making. I think the principle of early treatment is very key. The principle of shared decision making is very key—you want the patient to be a partner. So you want them to be informed and educated to have a true understanding about MS. And then I think principal factors are, what are individual goals and this would also account for, do they have comorbid conditions, what are their lifestyle expectations? Are they looking at pregnancy as something down the line that is important? So there are individual subject goals. There are MS disease goals. How active is their MS? What sort of prognostic profile does the patient have? Someone who has very active disease, somebody that you're very worried about, [they] look like they're fitting into a poor prognosis. Efficacy of your DMT choice now becomes very important, critically important. And then I think finally, the DMT. And this is the mode of delivery, the safety, the tolerability, the adverse events, the efficacy of the drug, the monitoring that is required. These are kind of the principal factors that are calculated into coming up with the best disease-modifying therapy choice for the individual patient.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
